Boosting the Body's army: new cell therapy aims to stop lung Cancer's return
NCT ID NCT07330037
Summary
This study is for people with a specific type of lung cancer (non-small cell) who had surgery after initial treatment, but some cancer cells likely remain. It tests whether adding a personalized cell therapy (L-TIL), made from the patient's own immune cells, to a standard immunotherapy drug (tislelizumab) can help keep the cancer from coming back. The main goal is to see if more patients are cancer-free two years after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.